HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the publication of new peer-reviewed research in Lasers in Medical Science demonstrating that its XTRAC 308nm Excimer Laser, when combined with 0.1% tacrolimus ointment, significantly improves treatment outcomes for plaque-type psoriasis compared with topical therapy alone.
The retrospective observational study, titled Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis, followed 100 adult patients treated between January 2023 and January 2024. Patients in the control group received tacrolimus ointment twice daily, while the observation group received the same regimen plus twice-weekly excimer laser sessions tailored to each individual’s Minimum Erythema Dose.
Results showed the combination therapy yielded a sharper reduction in Psoriasis Area and Severity Index (PASI) scores. The control group improved from 18.62 to 5.23, while the laser-plus-ointment group improved from 18.36 to 3.30, a statistically significant difference (p < 0.01). Safety outcomes were favorable in both groups, with no serious adverse events and only mild, self-limiting irritation reported in a few patients.
STRATA emphasized that individualized excimer dosing enabled targeted treatment of lesions while sparing healthy skin. Mechanistically, the laser induces apoptosis in pathogenic T-cells and suppresses keratinocyte proliferation, complementing tacrolimus’ localized calcineurin inhibition to reduce cytokine release.
“This important new study highlights the relevance and scientific rigor behind our Excimer laser technology,” said Dr. Dolev Rafaeli, STRATA’s President and CEO. “As clinicians increasingly seek personalized, flexible, and safe treatment options, our XTRAC system continues to meet the moment by integrating seamlessly with topical and systemic therapies. With more than 400 clinical publications backing Excimer therapy and a strong safety track record, this newest publication adds further weight to our case with CMS to expand reimbursement, especially as demand for non-biologic, in-office treatment options continues to grow.”
The findings reinforce STRATA’s strategic focus on personalized dermatologic care. By supporting combination therapy approaches, validating its clinical strategy, and providing cost-effective alternatives to systemic immunosuppressants, the company aims to broaden provider adoption and strengthen payer confidence in excimer-based psoriasis management.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.